Lung cancer is the leading cause of cancer death worldwide. Cigarette smoking is the most common risk factor for lung carcinoma; other risks include genetic factors and exposure to radon gas, asbestos, secondhand smoke, and air pollution. Nicotine, the primary addictive constituent of cigarettes, contributes to cancer progression through activation of nicotinic acetylcholine receptors (nAChRs), which are membrane ligand-gated ion channels. Activation of nicotine/nAChR signaling is associated with lung cancer risk and drug resistance. We focused on nAChR pathways activated by nicotine and its downstream signaling involved in regulating apoptotic factors of mitochondria and drug resistance in lung cancer. Increasing evidence suggests that several sirtuins play a critical role in multiple aspects of cancer drug resistance. Thus, understanding the consequences of crosstalk between nicotine/nAChRs and sirtuin signaling pathways in the regulation of drug resistance could be a critical implication for cancer therapy.

Original languageEnglish
Pages (from-to)1125-1140
Number of pages16
JournalJournal of Cancer
Issue number5
Publication statusPublished - Jan 1 2020


  • Drug resistance
  • Lung cancer
  • Mitochondria
  • Nicotinic acetylcholine receptor
  • Sirtuin

ASJC Scopus subject areas

  • Oncology


Dive into the research topics of 'Nicotinic-nAChR signaling mediates drug resistance in lung cancer'. Together they form a unique fingerprint.

Cite this